In this issue: 

>> FDA requests further data for VivaGel^® BV approval in the US

>> Launch of VivaGel^® BV in multiple territories

>> VivaGel^® BV licensed to ITF Pharma in the US

>> VivaGel^® condom approved in Japan

>> Clinical trials for internal DEP^® products progressing well

>> Patent published for AstraZeneca-DEP^® drugs: DEP^® Bcl2/xL inhibitors show compelling efficacy & synergy in combination

>> DEP^® docetaxel & DEP^® cabazitaxel outperformed both gemcitabine & Abraxane^®

>> SPL7013 eye drops for viral conjunctivitis

>> Partnering activities 

>> Macquarie initiates coverage of Starpharma

>> Outlook

 Download: Shareholder Update January 2019 (pdf file, 557kb)